ecancermedicalscience

Research

Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India

26 Sep 2022
Sandip Ganguly, Navonil Mukherjee, Sayan Mandal, Somnath Roy, Sanjit Agarwal, Bivas Biswas, Joydeep Ghosh

Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have shown marked benefit in the treatment of hormone positive metastatic breast cancer (HR+ MBC). There are limited real-world studies with palbociclib and ribociclib. Here we report our experience with CDK4/6 inhibitors in these groups of patients.

Material and methods: Patients with HR+ MBC who have received either palbociclib or ribociclib during the course of their treatment from January 2017 to January 2022 were included in the study. The baseline demographic features, treatment details and toxicity were recorded. Patients who received at least 1 month of therapy were included in the survival analysis.

Results: A total of 144 patients received CDK4/6 inhibitors during the time period. The median age of the population was 53 (30–80) years. Ninety-eight (71.4%) patients presented with de novo metastatic disease. The most common site of metastasis was to the skeleton (74.2%). Most patients (75%) received palbociclib as their therapy. At a median follow-up of 20.2 months, the median progression free survival (PFS) of the whole population was 16.5 (95% confidence interval (95% CI): 11.6–25.5) months and the median overall survival (OS) was 29.7 (95% CI: 21.7–44.6) months. The presence of liver metastases, low progesterone receptor positivity (Allred score < 6) and prior systemic treatment were poor prognostic factors for both PFS and OS in multivariate analysis. Drug was discontinued for only 2.1% of the patient population.

Conclusions: Use of CDK4/6 inhibitors has led to improvement in PFS and OS in patients with HR+ MBC and it is well tolerated. The presence of liver metastases and low progesterone receptor positivity (Allred score < 6) and prior treatment are poor prognostic factors.

Related Articles

Gbenro E. Olukiran, Adewumi O. Alabi, Anthonia C. Sowunmi, Babatunde Fadipe, Gbenga O. Popoola, Sunday A. Okinbaloye, Hnin L. Nwe Thein, Ololade Kehinde
Neha Singh, Sujata Agrawal, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Paramita Paul, Sadaf Haiyat, Akhil Kapoor, Anuj Gupta, Bal Krishna Mishra, Mayank Tripathi, Bipinesh Sansar
Victor Acosta Marín, Fernando Petracci, Denis U Landaverde, William Mantilla, Cynthia Villarreal, Guianeya Santander, Agatha Reyes, Joel Moreno, Ahmad Wali Mushtaq, Brizio Moreno, Juan Carlos Samamé
Maria Tereza Nieto-Coronel, Daniela Shveid Gerson, Gian Karla Urey Cuellar, Navia-Bueno Ma Pilar, Maribel Marmol Casas
Ashutosh Mishra, Amit Kumar, Ajay Gogia, Chinmay Bagla, Gajendra Pandit, Jyoti Sharma, Jyoutishman Saikia, Rohan Kapoor, D N Sharma, Atul Batra, Surendra Saini, Supriya Mallick, Nishkarsh Gupta, Brajesh Ratre, Ruchi Rathore, Sandeep Mathur, Sunil Kumar, Suryanarayana Deo
Moushumi Suryavanshi, Prashant Mehta, Manoj Kumar, Saphalta Bhagmar, Vidit Kapoor, Dushyant Kumar, Sweta Mishra, Bhawna Chauhan